deltatrials
Completed PHASE4 NCT03192826

Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy

Study of the Efficacy of Brinzolamide 1% Plus Brimonidine 0.2% Versus Brimonidine 0.2% in the Prevention of Intraocular Pressure Rise After Nd-YAG Laser Capsulotomy

Sponsor: University Hospital of Patras

Updated 11 times since 2017 Last updated: Jun 23, 2019 Started: Jun 20, 2016 Primary completion: Jul 8, 2017 Completion: Jul 8, 2017

A PHASE4 clinical study on Ocular Hypertension and Posterior Capsule Opacification, this trial is completed. The trial is conducted by University Hospital of Patras and has accumulated 11 data snapshots since 2016. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Change History

11 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE4

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE4

Show 6 earlier versions
  1. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE4

  2. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE4

  3. Aug 2019 — Jan 2021 [monthly]

    Completed PHASE4

  4. Jun 2018 — Aug 2019 [monthly]

    Completed PHASE4

  5. Aug 2017 — Jun 2018 [monthly]

    Completed PHASE4

    Status: RecruitingCompleted

  6. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE4

    First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University Hospital of Patras
Data source: University Hospital of Patras

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • Pátrai, Greece